Cargando…

Conditional Survival and Annual Hazard Estimates of Classical Hodgkin Lymphoma

BACKGROUND: In the present study, we have tried to understand how the level of risk and survival probability changes over time for patients with classical Hodgkin’s lymphoma by employing conditional survival and annual hazard as dynamic estimates of prognosis and survival. METHODS: This retrospectiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nuersulitan, Reyizha, Yang, Mingzi, Mi, Lan, Wu, Meng, Liu, Xin, Ping, Lingyan, Xie, Yan, Liu, Weiping, Song, Yuqin, Zhu, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405168/ https://www.ncbi.nlm.nih.gov/pubmed/34471386 http://dx.doi.org/10.2147/CMAR.S324543

Ejemplares similares

Effect of infection with hepatitis B virus on the survival outcome of diffuse large B-cell lymphoma in the prophylactic antiviral era
por: Nuersulitan, Reyizha, et al.
Publicado: (2022)

Conditional survival and hazards of death for peripheral T-cell lymphomas
por: Gao, Hongye, et al.
Publicado: (2021)

Management and clinical outcomes of follicular lymphoma across continuous lines of treatments: a retrospective analysis in China
por: Liu, Jiaxin, et al.
Publicado: (2023)

Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma
por: Liu, Weiping, et al.
Publicado: (2023)

Single or tandem autologous stem cell transplantation for treating Chinese patients with refractory/relapsed classical Hodgkin lymphoma
por: Zhang, Chen, et al.
Publicado: (2023)

Genetics of classical Hodgkin Lymphoma
por: Schiavoni, Gianluca, et al.
Publicado: (2018)

Composite follicular lymphoma and classic Hodgkin lymphoma
por: Kim, Han-Na, et al.
Publicado: (2022)

The molecular mechanisms of classic Hodgkin's lymphoma.
por: Felberbaum, Rachael S.
Publicado: (2005)

Immunological Deregulation in Classic Hodgkin Lymphoma
por: Romano, Alessandra, et al.
Publicado: (2014)

Controversies in the Treatment of Classical Hodgkin Lymphoma
por: Eichenauer, Dennis A., et al.
Publicado: (2018)

The Grey Zones of Classic Hodgkin Lymphoma
por: Bosch-Schips, Jan, et al.
Publicado: (2022)

The real risk of secondary non-Hodgkin lymphoma following classical Hodgkin lymphoma
por: Dogan, Ahmet
Publicado: (2022)

Classical Hodgkin Lymphoma Presenting as a Sigmoid Mass
por: Caulkins, Heather, et al.
Publicado: (2021)

Infused autograft lymphocyte to monocyte ratio predicts survival in classical Hodgkin lymphoma
por: Porrata, Luis F, et al.
Publicado: (2015)

PiwiRNA-651 as marker of treatment response and survival in classical Hodgkin lymphoma
por: Cordeiro, Anna, et al.
Publicado: (2016)

Bob-1 is expressed in classic Hodgkin lymphoma
por: Abd El All, Howayda S
Publicado: (2007)

Resources-Stratified Guidelines for Classical Hodgkin Lymphoma
por: Relecom, Allan, et al.
Publicado: (2020)

MicroRNA signature in classical Hodgkin lymphoma
por: Paczkowska, Julia, et al.
Publicado: (2021)

Bone marrow involvement by classic Hodgkin lymphoma
por: Barouqa, Mohammad, et al.
Publicado: (2022)

Aberrant synaptophysin expression in classic Hodgkin lymphoma
por: Im, Soyoung, et al.
Publicado: (2022)

Current directions in the treatment of classical Hodgkin lymphoma
por: Keller, Frank G., et al.
Publicado: (2023)

CAR-T Cell Therapy for Classical Hodgkin Lymphoma
por: Katsin, Mikalai, et al.
Publicado: (2023)

Metachronous mixed cellularity classical Hodgkin’s lymphoma and T-cell leukemia/lymphoma: A case report
por: Dong, Yang, et al.
Publicado: (2021)

Prognostic Impact of Tumor-Associated Macrophages on Survival Is Checkpoint Dependent in Classical Hodgkin Lymphoma
por: Karihtala, Kristiina, et al.
Publicado: (2020)

Novel Agents For Relapsed and Refractory Classical Hodgkin Lymphoma: A Review
por: Zhang, Yujie, et al.
Publicado: (2022)

Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas
por: Ye, Yingying, et al.
Publicado: (2021)

Treatment outcomes in classic Hodgkin lymphoma: 5‐year update from the Brazilian Hodgkin Lymphoma Registry
por: Biasoli, Irene, et al.
Publicado: (2023)

The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future
por: Richardson, S. E., et al.
Publicado: (2011)

Hemophagocytic Lymphohistiocytosis in a Patient with Classical Hodgkin Lymphoma
por: Hyun, G., et al.
Publicado: (2016)

The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma
por: Meti, Nicholas, et al.
Publicado: (2018)

Combined linkage and association analysis of classical Hodgkin lymphoma
por: Lawrie, Alastair, et al.
Publicado: (2018)

Mucocutaneous Paraneoplastic Syndrome Secondary to Classical Hodgkin’s Lymphoma
por: Jurkovic, Jenna, et al.
Publicado: (2019)

Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
por: Voorhees, Timothy J, et al.
Publicado: (2020)

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
por: Lai, Catherine, et al.
Publicado: (2019)

Classical Hodgkin’s Lymphoma in the Era of Immune Checkpoint Inhibition
por: De Re, Valli, et al.
Publicado: (2019)

Cell-Free DNA for the Management of Classical Hodgkin Lymphoma
por: Camus, Vincent, et al.
Publicado: (2021)

Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma
por: Tarekegn, Kidist, et al.
Publicado: (2021)

Optimization of the first line treatment in classical Hodgkin's lymphoma
por: Brice, Pauline
Publicado: (2018)

Checkpoint CD47 expression in classical Hodgkin lymphoma
por: Gholiha, Alex Reza, et al.
Publicado: (2022)

Novel Approaches in Molecular Characterization of Classical Hodgkin Lymphoma
por: van Bladel, Diede A. G., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c3kprvenic7v2nq7mkfadlu4u7